Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSR149415 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| SSR149415 - 250 mg | EXPERIMENTAL | SSR149415 250 mg, twice daily for a maximum of 8 weeks |
| SSR149415 - 100 mg | EXPERIMENTAL | SSR149415 100 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks |
| Paroxetine | ACTIVE_COMPARATOR | Paroxetine 20 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo for a maximum of 9 weeks |
| Name | Type | Description |
|---|---|---|
| SSR149415 | DRUG | - |
| Placebo | DRUG | Oral administration (capsules) |
| Paroxetine | DRUG | Oral administration (capsules) |
Inclusion Criteria: * Diagnosis of major depressive disorder, recurrent, as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) criteria (296.3) and confirmed by the semi-structured Mini International Neuropsychiatric Interview (MINI) Exclusion ...
SSR149415 is an investigational small molecule being developed by Sanofi for the treatment of anxiety disorders and depressive disorder. It has been studied in Phase 2 clinical trials for major depressive disorder and generalized anxiety disorder, though it is not approved and remains in clinical development.
SSR149415 is a small molecule developed by Sanofi for psychiatric conditions. Its specific molecular target has not been disclosed in the available clinical trial information, so its mechanism of action is not detailed here.
SSR149415 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is an investigational small molecule intended for the treatment of anxiety disorders and depressive disorder.
SSR149415 is in Phase 2 clinical development. It has completed three Phase 2 trials, including studies in major depressive disorder and generalized anxiety disorder. The drug is investigational and has not received FDA approval.
SSR149415 has completed three Phase 2 trials: NCT00358631 and NCT00361491 for major depressive disorder, and NCT00374166 for generalized anxiety disorder. These trials enrolled a total of 968 participants across multiple countries, including the United States, Argentina, Bulgaria, Canada, Chile, Croatia, Mexico, and Russia.
SSR149415 is the only name provided for this investigational drug. No alternative names or brand names have been associated with it in the available information, so it is not known to be the same as any other marketed medication.